32
EQUINE VETERINARY EDUCATION / AE / JANUARY 2017
McDonald, W.S. and Nichter, L.S. (1994) Debridement of bacterial and particulate-contaminated wounds. Ann. Plast. Surg. 33, 142-147.
Mcllwraith, C.W. (1989) Erkrankungen der Gelenke, Sehnen, B€ ander
sowie ihrer Hilfseinrichtungen. In: Adams’ Lahmheit bei Pferden, Ed.: T.S. Stashak, Lea & Febiger, Philadelphia, Pennsylvania. pp 339-485.
M endez-Fern
andez, M.A. (1993) Treatment of chronic recurrent synovial fistulae with myofascial flaps. Br. J. Plast. Surg. 46, 303-306.
Odumala, O.O., Ayekoloye, C.I. and Perera, S.D. (2001) Synovial knee fistula: a cause of prolonged morbidity. Arthroscopy 17, 640-641.
Orsini, J.A. (2005) Use of vacuum-assisted closure for management of traumatic wounds. Equine Vet. Educ. 17, 27-32.
Proffer, D.S., Drez, D. Jr and Daus, G.P. (1991) Synovial fistula of the knee: a complication of arthroscopy. Arthroscopy 7, 98-100.
Rheiner, B., Ehrle, A., K€ onig, S. and Lischer, C. (2011)
Ultraschallassistierte Wundbehandlung einer chronisch infizierten, schwer heilenden Wunde an der Unterbrust eines Pferdes. Pferdeheilkunde 27, 597-600.
Rijkenhuizen, A.B.M., van den Boom, R., Landman, M. and Cornelissen, B.P.M. (2005) Can vacuum assisted wound management enhance graft acceptance? Pferdeheilkunde 21, 413-418.
Sanchez Teran, A.F., Rubio-Martinez, L.M., Villarino, N.F. and Sanz, M.G. (2012) Effects of repeated intra-articular administration of amikacin on serum amyloid A, total protein and nucleated cell count in synovial fluid from healthy horses. Equine Vet. J. 44, Suppl. 43, 12-16.
Schneider, R.K. (1998). Common bacteria encountered in septic arthritis. Proc. Am. Ass. Equine Practnrs. 44, 152-158.
Schneider, R.K., Bramlage, L.R., Moore, R.M., Mecklenburg, L.M., Kohn, C.W. and Gabel, A.A. (1992) A retrospective study of 192 horses affected with septic arthritis/tenosynovitis. Equine Vet. J. 24, 436-442.
Schultheiss, H.L. 2006.Ultrasound-assisted wound bed preparation. Podiatry Management 116, 125-127.
Smith, L.C.R. (2009) Treatment of a cyst-like synovial hernia associated with the digital flexor tendon sheath of a 17-year-old pony. J. Equine. Vet. Sci. 29, 786-790.
Theoret, C.L. (2004) Wound repair in the horse: problems and proposed innovative solutions. Clin. Tech. Equine Pract. 3, 134-140.
Voermans, M., van Soest, J.M., van Duijkeren, E. and Ensink, J.M. (2006) Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. J. Vet. Pharmacol. Therapeut. 29, 555-560.
Wilson, D.G. (1989) Synovial hernia as a possible complication of arthroscopic surgery in a horse. J. Am. Vet. Med. Ass. 194, 1071-1072.
Yiannakopoulos, C.K. (2007) Diagnosis and treatment of postarthroscopic synovial knee fistulae. J. Knee Surg. 20, 34-38.
Zantingh, A.J., Schwark, W.S., Fubini, S.L. and Watts, A.E. (2014) Accumulation of amikacin in synovial fluid after regional limb perfusion of amikacin sulfate alone and in combination with ticarcillin/clavulanate in horses. Vet. Surg. 43, 282-288.
CAUTION
Federal Law restricts this drug to use by or on the order of a licensed veterinarian.
LEGEND® Multi (hyaluronate sodium) Dose
For Intravenous Use in Horses Only Not for Intra-Articular Use and
(hyaluronate sodium) LEGEND®
Injectable Solution 4 mL For Intravenous Use In Horses Only
2 mL For Intravenous or Intra-Articular Use In Horses Only
BRIEF SUMMARY
Prior to use please consult the product insert, a summary of which follows:
Injectable Solution and LEGEND® Multi Dose Injectable Solution are indicated in the treatment of equine joint dysfunction associated with equine osteoarthritis.
INDICATIONS LEGEND®
CONTRAINDICATIONS
There are no known contraindications for the use of LEGEND® LEGEND® horses.
RESIDUE WARNINGS
Do not use in horses intended for human consumption.
HUMAN WARNINGS
Not for use in humans. Keep out of reach of children.
ADVERSE REACTIONS
No side effects were observed in LEGEND Injectable Solution clinical field trials. Side effects reported post-approval: Following intravenous use: Occasional depression, lethargy, and fever. Following intra-articular (LEGEND Injectable Solution – 2 mL only) use: joint or injection site swelling and joint pain. For medical emergencies or to report adverse reactions, call 1-800-422-9874.
Injectable Solution and Multi Dose Injectable Solution in
ANIMAL SAFETY WARNING
For LEGEND Injectable Solution 4 mL and LEGEND Multi Dose Injectable Solution – Not for Intra-articular use. The Intra-articular safety of hyaluronate sodium with benzyl alcohol has not been evaluated.
PRECAUTIONS
Complete lameness evaluation should be conducted by a veterinarian. Sterile procedure during the injection process must be followed. Intra-articular injections should not be made through skin that is inflamed, infected or has had a topical product applied. The safety of LEGEND Injectable Solution and LEGEND Multi Dose has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.
ANIMAL SAFETY SUMMARY
Animal safety studies utilizing LEGEND Multi Dose Injectable Solution were not performed. LEGEND Multi Dose Injectable Solution was approved based on the conclusion that the safety of LEGEND Multi Dose Injectable Solution will not differ from that demonstrated for the original formulation of LEGEND Injectable Solution. LEGEND Injectable Solution was administered to normal horses at one, three and five times the recommended intra-articular dosage of 20 mg and the intravenous dose of 40 mg. Treatments were given weekly for nine consecutive weeks. No adverse clinical or clinical pathologic signs were observed. Injection site swelling of the joint capsule was similar to that seen in the saline treated control horses. No gross or histological lesions were observed in areas of the treated joint.
For customer care or to obtain product information, including a Material Safety Data Sheet, call
1-888-637-4251 Option 2.
®LEGEND is a registered trademark, and ™ the Horse Logo is a trademark, of Merial. ©2016 Merial, Inc., Duluth, GA. All rights reserved.
© 2015 EVJ Ltd
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
